South Korea’s Celltrion (Kosdaq: 068270) has announced the US launch of Steqeyma (ustekinumab-stba), a biosimilar to Stelara ...

STEQEYMA®, one of the first-wave biosimilars to STELARA®, is now available in the U.S. Approved for the same indications as ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug ...

A college student from Anthony is speaking out after Blue Cross and Blue Shield of Kansas denied a medicine she has been ...

I often say that investing rarely has a dull moment, which is why I find it so fascinating. The beginning of 2025 certainly ...

Four companies have applied to Health Canada to sell copies of Ozempic after its market exclusivity expires on Jan. 4, 2026 ...

It will be the first biosimilar offered by MCCPDC ... regularly appearing top or high on the list of drugs with unwarranted increases compiled by the Institute for Clinical and Economic Review ...

Last year, Alteogen also signed an agreement with Sandoz to develop Hybrozyme-based versions of an undisclosed biosimilar drug, with an option ... back of a lengthening list of indications across ...

The Travelers Companies, Inc. today introduced Travelers Synergy?, a new customizable product liability coverage tailored to life sciences companies. The offering will help medical technology, ...